LEUVEN, Belgium, March 27 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that Global Opportunities Capital Asset Management BV, also known as GO Capital, a Dutch-based asset manager, has acquired 1.2 million shares in the company, representing approximately 5.4% of its outstanding shares. The acquisition of this stake from Biggar Limited makes GO Capital one of ThromboGenics' major shareholders. As a result of this transaction, Biggar's holding in ThromboGenics is reduced to 33.5%.
